ArticlePloS one2022

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

Lisa A de Jong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.